Development of a vaccine against Staphylococcus aureus invasive infections: Evidence based on human immunity, genetics and bacterial evasion mechanisms.

Journal Article (Journal Article;Review)

Invasive Staphylococcus aureus infections are a leading cause of morbidity and mortality in both hospital and community settings, especially with the widespread emergence of virulent and multi-drug resistant methicillin-resistant S. aureus strains. There is an urgent and unmet clinical need for non-antibiotic immune-based approaches to treat these infections as the increasing antibiotic resistance is creating a serious threat to public health. However, all vaccination attempts aimed at preventing S. aureus invasive infections have failed in human trials, especially all vaccines aimed at generating high titers of opsonic antibodies against S. aureus surface antigens to facilitate antibody-mediated bacterial clearance. In this review, we summarize the data from humans regarding the immune responses that protect against invasive S. aureus infections as well as host genetic factors and bacterial evasion mechanisms, which are important to consider for the future development of effective and successful vaccines and immunotherapies against invasive S. aureus infections in humans. The evidence presented form the basis for a hypothesis that staphylococcal toxins (including superantigens and pore-forming toxins) are important virulence factors, and targeting the neutralization of these toxins are more likely to provide a therapeutic benefit in contrast to prior vaccine attempts to generate antibodies to facilitate opsonophagocytosis.

Full Text

Duke Authors

Cited Authors

  • Miller, LS; Fowler, VG; Shukla, SK; Rose, WE; Proctor, RA

Published Date

  • January 1, 2020

Published In

Volume / Issue

  • 44 / 1

Start / End Page

  • 123 - 153

PubMed ID

  • 31841134

Pubmed Central ID

  • PMC7053580

Electronic International Standard Serial Number (EISSN)

  • 1574-6976

Digital Object Identifier (DOI)

  • 10.1093/femsre/fuz030


  • eng

Conference Location

  • England